BIN1 Protein Biomarker for Heart Failure Prognosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack a reliable marker for assessing the steady-state biochemical health of the heart and predicting future outcomes in heart failure patients, particularly for chronic heart failure and arrhythmogenic right ventricular cardiomyopathy.
Innovation Solution
Determining BIN1 protein levels in bodily fluid samples, such as blood, serum, or plasma, to assess heart failure presence, predict cardiac mortality risk, and evaluate cardiac health, with decreased levels correlating to poor cardiac health and increased mortality risk.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional heart failure markers are used, then diagnosis of acute heart failure and myocardial infarction is improved, but assessment of steady-state biochemical health and prediction of future outcomes deteriorates
Solution Approach 1:
The patent shifts from using conventional acute heart failure markers to measuring BIN1 protein levels, representing a fundamental parameter change in the biomarker being assessed. This enables both accurate diagnosis and reliable long-term prognosis by capturing steady-state biochemical health rather than just acute events
2Productivity
If existing cardiac biomarkers are used, then acute heart failure diagnosis is improved, but prediction of cardiac mortality and future outcomes deteriorates
Solution Approach 1:
The BIN1 protein marker serves multiple functions simultaneously: it diagnoses acute heart failure, assesses steady-state biochemical health, and predicts future cardiac outcomes including mortality. This multi-functional biomarker eliminates the need for separate diagnostic and prognostic tests, preserving comprehensive clinical information
3Measurement precision
If traditional heart failure assessment methods are used, then acute condition detection is improved, but chronic heart failure monitoring and treatment evaluation deteriorates
Solution Approach 1:
The BIN1 protein level measurement provides continuous useful action across the entire spectrum of heart failure management: from acute diagnosis through chronic monitoring to treatment evaluation. The marker remains stable and informative over time, enabling ongoing assessment rather than isolated acute measurements
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 3A~3B
AI summary
The present disclosure provides methods involving use of BIN1 protein levels in biological fluid of a subject in evaluating cardiac health of the subject. The method provided herein may be used to predict a risk of a poor outcome in a subject. The methods also find use in evaluating subjects for assessing patients diagnosed with heart failure. These methods are also useful in assessing therapy options and efficacy of treatment in heart failure patients.